Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report report published on Thursday morning, Benzinga reports. They currently have a $7.00 price target on the stock.

Several other research analysts also recently weighed in on the company. Chardan Capital increased their price target on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a buy rating in a research note on Thursday, March 21st. Piper Sandler assumed coverage on shares of Taysha Gene Therapies in a research report on Tuesday, April 9th. They set an overweight rating and a $9.00 target price for the company. Cantor Fitzgerald reissued an overweight rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, April 30th. Canaccord Genuity Group reaffirmed a buy rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Finally, JMP Securities reiterated a market outperform rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Taysha Gene Therapies has a consensus rating of Buy and a consensus price target of $6.88.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $2.57 on Thursday. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54. Taysha Gene Therapies has a 52 week low of $0.50 and a 52 week high of $3.89. The firm’s 50-day simple moving average is $2.65 and its two-hundred day simple moving average is $2.10.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $4.75 million. On average, equities research analysts forecast that Taysha Gene Therapies will post -0.39 earnings per share for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its stake in Taysha Gene Therapies by 44.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 26,971 shares of the company’s stock worth $85,000 after purchasing an additional 8,246 shares in the last quarter. Kovitz Investment Group Partners LLC increased its holdings in shares of Taysha Gene Therapies by 66.7% in the third quarter. Kovitz Investment Group Partners LLC now owns 25,000 shares of the company’s stock worth $79,000 after purchasing an additional 10,000 shares during the period. Howard Capital Management Inc. purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $25,000. China Universal Asset Management Co. Ltd. boosted its stake in Taysha Gene Therapies by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock valued at $103,000 after buying an additional 14,286 shares during the period. Finally, Victory Capital Management Inc. purchased a new position in Taysha Gene Therapies during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.